Use of Arterio-venous Fistula as First Choice for Intravenous Drug Administration in Kidney Transplant Recipients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02874391

Acronym

PerFAV

Enrollment

Registered

2016-08-22

Start date

2016-09-30

Completion date

2019-09-30

Last updated

2017-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Evaluate the Risks of Using Arteriovenous Fistula as First Choise for Drug Administration

Brief summary

Use of arteriovenous fistula for IV drug administration is controversial and often prohibited by nephrologists. However, we have been using this method in our department for years now in order to keep the patients 'veins for other fistulas in the future. The aim of this study is to evaluate our practice and maybe provide a justification for a larger multi-center study given the importance of this subject in patients with chronic renal failure.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \> 18 years, functional AV fistula, new kidney transplant recipient

Exclusion criteria

* Prothetic AV fistula, Very recent AV fistula of less than 3 months

Design outcomes

Primary

Measure	Time frame
Evaluate the risk of complications of AV fistula	12 months

Countries

France

Contacts

Primary ContactChristelle Roux

Christelle.Roux@chu-angers.fr

Outcome results